ReviewFrontiers in cellular and infection microbiology2022
An Update of Mobile Colistin Resistance in Non-Fermentative Gram-Negative Bacilli.
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Genomic characterization of non-fermenting gram-negative bacilli with metallo beta lactamase production and mcr based colistin resistance causing soft tissue infections: a seven-year hospital based prospective cross-sectional study.Molecular biology reports · 2026Article
- WGS reveals high-risk clones of Pseudomonas aeruginosa harbouring extensive antimicrobial and predicted anti-phage defense systems recovered from diabetic foot ulcer patients in Egypt.BMC microbiology · 2026Article
- Evaluation of the combined efficacy of carvone and colistin against colistin-resistantMicrobiology spectrum · 2026Article
- Review
- First Report and Comprehensive Risk Index ofMicroorganisms · 2026Article
- In Vitro Antimicrobial Activities of Carbapenem-beta Lactamase Inhibitor Combinations Against Carbapenem-resistant Gram-negative Pathogens Isolated from Türkiye.Current microbiology · 2026Article
- Integrated Proteomics and Metabolomics Reveal Multifaceted Mechanisms of Colistin Resistance inInfection and drug resistance · 2026Article
- Effects of colistin stress on growth, antioxidant system and metabolite pattern of lettuce.BMC plant biology · 2025Article
- Molecular Surveillance of ESBL and Carbapenemase Genes in Gram-Negative Bacterial Pathogens Isolated from Various Clinical Samples Collected from Northern Region of United Arab Emirates.Microorganisms · 2025Article
- Evaluation of Colistin Susceptibility in Carbapenem-Resistant Acinetobacter baumannii Isolates Using Broth Microdilution, MICRONAUT-MIC-Strip, and VITEK MS.MicrobiologyOpen · 2025Article
- When the Last Line Fails: Characterization of Colistin-ResistantPathogens (Basel, Switzerland) · 2025Article
- Efficacy of Endolysin LysAB1245 Combined with Colistin as Adjunctive Therapy Against Colistin-Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2025Article
- Genomic Study of High-Risk Clones ofAntibiotics (Basel, Switzerland) · 2024Article
- Treatment Strategies of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2024Review
- Efficacy of Tamoxifen Metabolites in Combination with Colistin and Tigecycline in Experimental Murine Models ofAntibiotics (Basel, Switzerland) · 2024Article
- Emergence of carbapenem resistant gram-negative pathogens with high rate of colistin resistance in Egypt: A cross sectional study to assess resistance trends during the COVID-19 pandemic.Journal, genetic engineering & biotechnology · 2024Article
- Molecular characterization of carbapenemase-producing Enterobacterales in a tertiary hospital in Lima, Peru.Microbiology spectrum · 2024Article
- Physicochemical properties of stingless bees (Meliponula beccarii) honey in Dandi and Meta Robi districts of West Shewa zone, Ethiopia.PloS one · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin, the last resort for multidrug and extensively drug-resistant bacterial infection treatment, was reintroduced after being avoided in clinical settings from the 1970s to the 1990s because of its high toxicity. Colistin is considered a crucial treatment option for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.